|Bid||1.7000 x 1300|
|Ask||2.4900 x 1100|
|Day's Range||1.8400 - 2.0600|
|52 Week Range||1.6100 - 15.1030|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
Subscribe to Yahoo Finance Plus to view Fair Value for SNCE
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”) the Agile Clinical Trial Operating System™, today reported its financial results for the quarter ended June 30, 2022. "We made meaningful strides across our strategic priorities in the second quarter and our pathway to profitability. We believe this commitment has materialized into strong revenue growth, sales pipeline expansion, and notably, margin improvement and sustainable
RESEARCH TRIANGLE PARK, N.C., July 28, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report second quarter 2022 financial results before the market opens on Thursday, August 11, 2022. Company management will host a corresponding conference call at 8:30 a.m. Eastern Time. The conference call can be accessed by registering online for dial-in information or via live audio webcast at: https://investors.science37.
If you want to know who really controls Science 37 Holdings, Inc. ( NASDAQ:SNCE ), then you'll have to look at the...